{"id":65324,"date":"2026-05-14T19:42:40","date_gmt":"2026-05-14T11:42:40","guid":{"rendered":"https:\/\/flcube.com\/?p=65324"},"modified":"2026-05-14T19:42:41","modified_gmt":"2026-05-14T11:42:41","slug":"chinas-cde-reports-record-drug-review-activity-in-2025-breakthrough-therapy-designations-surge-11-as-regulatory-filings-hit-20149","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65324","title":{"rendered":"China&#8217;s CDE Reports Record Drug Review Activity in 2025 \u2013 Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149"},"content":{"rendered":"\n<p>China&#8217;s <strong>Center for Drug Evaluation (CDE)<\/strong> released its <strong>2025 Annual Drug Review Report<\/strong>, revealing <strong>record regulatory activity<\/strong> with <strong>20,149 drug filings accepted<\/strong> (+3% YOY) and <strong>19,375 reviews completed<\/strong> (+6.11% YOY). The report highlights accelerating innovation, with <strong>Breakthrough Therapy Designations (BTD) granted to 101 applications<\/strong> (+10.99% YOY) and <strong>priority review approvals up 7.26%<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-regulatory-metrics-2025-performance-overview\">Key Regulatory Metrics \u2013 2025 Performance Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2025 Total<\/th><th>YOY Change<\/th><th>Composition<\/th><\/tr><\/thead><tbody><tr><td><strong>Filings Accepted<\/strong><\/td><td>20,149<\/td><td>+3.00%<\/td><td>18,448 drug products (+5.56%) + 1,701 APIs<\/td><\/tr><tr><td><strong>Reviews Completed<\/strong><\/td><td>19,375<\/td><td>+6.11%<\/td><td>17,679 drug products (+9.69%) + 1,696 APIs<\/td><\/tr><tr><td><strong>Technical Reviews<\/strong><\/td><td>15,408<\/td><td>+10.75%<\/td><td>Drug product formulations requiring full assessment<\/td><\/tr><tr><td><strong>Administrative Approvals<\/strong><\/td><td>2,271<\/td><td>Direct processing<\/td><td>Supplemental applications &amp; one-time imports<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-innovation-acceleration-indicators\">Innovation Acceleration Indicators<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-breakthrough-therapy-designation-btd-program\">Breakthrough Therapy Designation (BTD) Program<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Applications Received:<\/strong> 424 BTD requests<\/li>\n\n\n\n<li><strong>Designations Granted:<\/strong> <strong>101 applications<\/strong> covering <strong>89 indications<\/strong><\/li>\n\n\n\n<li><strong>Approval Rate:<\/strong> <strong>23.82%<\/strong> of submitted applications<\/li>\n\n\n\n<li><strong>Growth:<\/strong> <strong>+10.99%<\/strong> increase in granted designations vs. 2024<\/li>\n\n\n\n<li><strong>Strategic Impact:<\/strong> Accelerated development pathways for high-need therapeutic areas<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-priority-review-amp-conditional-approval-programs\">Priority Review &amp; Conditional Approval Programs<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Priority Review Grants:<\/strong> <strong>133 filings<\/strong> (92 varieties) \u2013 <strong>+7.26% YOY<\/strong><\/li>\n\n\n\n<li><strong>Conditional Approvals:<\/strong> <strong>38 filings<\/strong> covering <strong>24 indications<\/strong><\/li>\n\n\n\n<li><strong>First-in-Class Approvals:<\/strong> <strong>21 indications<\/strong> received their inaugural market authorization<\/li>\n\n\n\n<li><strong>Regulatory Flexibility:<\/strong> Conditional pathway enables earlier patient access to promising therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-stakeholder-engagement-amp-communication-services\">Stakeholder Engagement &amp; Communication Services<\/h2>\n\n\n\n<p>The CDE significantly enhanced industry interaction in 2025:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Communication Requests:<\/strong> <strong>5,181<\/strong> meetings requested by industry<\/li>\n\n\n\n<li><strong>Requests Processed:<\/strong> <strong>4,049<\/strong> drug varieties supported across <strong>1,783 companies<\/strong><\/li>\n\n\n\n<li><strong>Direct Meetings:<\/strong> <strong>824 face-to-face or telephone meetings<\/strong> \u2013 <strong>+19.25% YOY<\/strong><\/li>\n\n\n\n<li><strong>Service Efficiency:<\/strong> <strong>4,705 requests processed<\/strong> out of 5,181 received (90.8% fulfillment rate)<\/li>\n<\/ul>\n\n\n\n<p>This represents a substantial increase in regulatory-industry collaboration, facilitating more efficient drug development through enhanced guidance and feedback mechanisms.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications-amp-strategic-trends\">Market Implications &amp; Strategic Trends<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pharmaceutical-industry-impact\">Pharmaceutical Industry Impact<\/h3>\n\n\n\n<p><strong>Accelerated Development Timelines:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>BTD and priority review programs compress time-to-market for innovative therapies<\/li>\n\n\n\n<li>Enhanced communication services reduce development uncertainty and costly delays<\/li>\n\n\n\n<li>Conditional approval pathway provides earlier revenue generation opportunities<\/li>\n<\/ul>\n\n\n\n<p><strong>Competitive Landscape Evolution:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>21 first-in-class approvals<\/strong> indicate robust innovation ecosystem<\/li>\n\n\n\n<li>Increased technical review volume (+10.75%) suggests complex novel modalities entering pipeline<\/li>\n\n\n\n<li>API filing growth reflects domestic manufacturing capacity expansion<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regulatory-system-maturation\">Regulatory System Maturation<\/h3>\n\n\n\n<p><strong>Operational Efficiency:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Review completion growth (+6.11%) outpaces filing acceptance (+3%), indicating improved throughput<\/li>\n\n\n\n<li>High communication request fulfillment rate demonstrates responsive regulatory infrastructure<\/li>\n\n\n\n<li>Administrative approval stream maintains efficiency for routine submissions<\/li>\n<\/ul>\n\n\n\n<p><strong>Innovation-Focused Framework:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>BTD program success rate (23.82%) balances accessibility with meaningful threshold<\/li>\n\n\n\n<li>Priority review expansion supports strategic national health priorities<\/li>\n\n\n\n<li>Conditional approval mechanism aligns with global regulatory harmonization trends<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-regulatory-environment\">Forward-Looking Regulatory Environment<\/h2>\n\n\n\n<p>The 2025 data demonstrates China&#8217;s regulatory system successfully scaling to accommodate both volume growth and innovation complexity. The <strong>dual-track approach<\/strong>\u2014maintaining efficient processing for standard applications while providing accelerated pathways for breakthrough innovations\u2014positions China as an increasingly attractive jurisdiction for global drug development.<\/p>\n\n\n\n<p>The significant increase in direct stakeholder engagement (+19.25% meetings) suggests the CDE is proactively supporting industry through the complexities of modern drug development, potentially reducing late-stage attrition and improving overall R&amp;D productivity.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory trends, industry dynamics, and policy impacts based on historical CDE data. Actual future outcomes may vary based on evolving regulatory frameworks, industry adaptation, competitive dynamics, and global healthcare developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s Center for Drug Evaluation (CDE) released its 2025 Annual Drug Review Report, revealing record&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[102],"class_list":["post-65324","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-cde"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s CDE Reports Record Drug Review Activity in 2025 \u2013 Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s Center for Drug Evaluation (CDE) released its 2025 Annual Drug Review Report, revealing record regulatory activity with 20,149 drug filings accepted (+3% YOY) and 19,375 reviews completed (+6.11% YOY). The report highlights accelerating innovation, with Breakthrough Therapy Designations (BTD) granted to 101 applications (+10.99% YOY) and priority review approvals up 7.26%.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65324\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s CDE Reports Record Drug Review Activity in 2025 \u2013 Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149\" \/>\n<meta property=\"og:description\" content=\"China&#039;s Center for Drug Evaluation (CDE) released its 2025 Annual Drug Review Report, revealing record regulatory activity with 20,149 drug filings accepted (+3% YOY) and 19,375 reviews completed (+6.11% YOY). The report highlights accelerating innovation, with Breakthrough Therapy Designations (BTD) granted to 101 applications (+10.99% YOY) and priority review approvals up 7.26%.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65324\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T11:42:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T11:42:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65324#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65324\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s CDE Reports Record Drug Review Activity in 2025 \u2013 Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149\",\"datePublished\":\"2026-05-14T11:42:40+00:00\",\"dateModified\":\"2026-05-14T11:42:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65324\"},\"wordCount\":479,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CDE\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65324#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65324\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65324\",\"name\":\"China's CDE Reports Record Drug Review Activity in 2025 \u2013 Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-14T11:42:40+00:00\",\"dateModified\":\"2026-05-14T11:42:41+00:00\",\"description\":\"China's Center for Drug Evaluation (CDE) released its 2025 Annual Drug Review Report, revealing record regulatory activity with 20,149 drug filings accepted (+3% YOY) and 19,375 reviews completed (+6.11% YOY). The report highlights accelerating innovation, with Breakthrough Therapy Designations (BTD) granted to 101 applications (+10.99% YOY) and priority review approvals up 7.26%.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65324#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65324\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65324#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s CDE Reports Record Drug Review Activity in 2025 \u2013 Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's CDE Reports Record Drug Review Activity in 2025 \u2013 Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149 - Insight, China&#039;s Pharmaceutical Industry","description":"China's Center for Drug Evaluation (CDE) released its 2025 Annual Drug Review Report, revealing record regulatory activity with 20,149 drug filings accepted (+3% YOY) and 19,375 reviews completed (+6.11% YOY). The report highlights accelerating innovation, with Breakthrough Therapy Designations (BTD) granted to 101 applications (+10.99% YOY) and priority review approvals up 7.26%.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65324","og_locale":"en_US","og_type":"article","og_title":"China's CDE Reports Record Drug Review Activity in 2025 \u2013 Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149","og_description":"China's Center for Drug Evaluation (CDE) released its 2025 Annual Drug Review Report, revealing record regulatory activity with 20,149 drug filings accepted (+3% YOY) and 19,375 reviews completed (+6.11% YOY). The report highlights accelerating innovation, with Breakthrough Therapy Designations (BTD) granted to 101 applications (+10.99% YOY) and priority review approvals up 7.26%.","og_url":"https:\/\/flcube.com\/?p=65324","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-14T11:42:40+00:00","article_modified_time":"2026-05-14T11:42:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65324#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65324"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s CDE Reports Record Drug Review Activity in 2025 \u2013 Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149","datePublished":"2026-05-14T11:42:40+00:00","dateModified":"2026-05-14T11:42:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65324"},"wordCount":479,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CDE"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65324#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65324","url":"https:\/\/flcube.com\/?p=65324","name":"China's CDE Reports Record Drug Review Activity in 2025 \u2013 Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-14T11:42:40+00:00","dateModified":"2026-05-14T11:42:41+00:00","description":"China's Center for Drug Evaluation (CDE) released its 2025 Annual Drug Review Report, revealing record regulatory activity with 20,149 drug filings accepted (+3% YOY) and 19,375 reviews completed (+6.11% YOY). The report highlights accelerating innovation, with Breakthrough Therapy Designations (BTD) granted to 101 applications (+10.99% YOY) and priority review approvals up 7.26%.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65324#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65324"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65324#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s CDE Reports Record Drug Review Activity in 2025 \u2013 Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65324"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65324\/revisions"}],"predecessor-version":[{"id":65325,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65324\/revisions\/65325"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}